速递｜GLP-1受体激动剂，可能改善类风湿关节炎症状

Core Viewpoint - GLP-1 receptor agonists (GLP-1RAs) show potential benefits for overweight or obese rheumatoid arthritis (RA) patients, beyond their established use for obesity and type 2 diabetes treatment [4][6]. Group 1: Research Findings - A study published in ACR Open Rheumatology indicates that GLP-1RAs can reduce disease activity and improve cardiovascular risk indicators in RA patients with a BMI ≥ 27 [4][6]. - The study included 173 RA patients treated with GLP-1RAs and a control group of 42 patients who were prescribed but did not use the medication [6]. - Significant improvements were observed in various clinical endpoints for the treatment group compared to the control group, including: - Disease activity score decreased by an average of -0.03 vs +0.2 (P=0.03) - Visual analog scale pain score improved by -0.6 cm vs +1.3 cm (P<0.001) - Weight loss of -4.4 kg vs -1.2 kg (P<0.001) - Total cholesterol reduction of -10.3 mg/dL vs +0.3 mg/dL (P=0.04) - Hemoglobin A1c decrease of -0.3% vs -0.01% (P=0.03) [6][7]. Group 2: Implications and Recommendations - The study suggests that GLP-1RAs may provide independent cardiovascular benefits beyond weight loss, potentially alleviating obesity-related inflammation in RA patients [7]. - However, nearly one-third of the treatment group discontinued the medication, primarily due to gastrointestinal side effects and accessibility issues, which could hinder clinical benefits [7]. - The study highlights disparities in accessibility, noting a higher proportion of white patients in the treatment group (71% vs 47% in the control group), indicating structural barriers that may limit access for Black, Latino, and Asian patients [7]. - Future research should prioritize increasing sample diversity to better reflect the RA population and confirm the findings through more rigorous prospective studies [7][8].